Compare SYNA & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYNA | EWTX |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.7B |
| IPO Year | 2001 | 2021 |
| Metric | SYNA | EWTX |
|---|---|---|
| Price | $126.62 | $44.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $100.78 | $39.00 |
| AVG Volume (30 Days) | 1.4M | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $663,588,000.00 | N/A |
| Revenue This Year | $12.63 | N/A |
| Revenue Next Year | $9.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.04 | N/A |
| 52 Week Low | $58.28 | $12.31 |
| 52 Week High | $149.11 | $48.40 |
| Indicator | SYNA | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.58 | 62.42 |
| Support Level | $122.18 | $29.03 |
| Resistance Level | $147.97 | N/A |
| Average True Range (ATR) | 7.83 | 2.71 |
| MACD | -0.77 | 0.62 |
| Stochastic Oscillator | 34.39 | 69.29 |
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. It operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products. The company geographically, it derives a majority of revenue from China, and also has its presence in Taiwan, Japan, South Korea, United States and Other countries.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.